Originally published as JCO Early Release 10.1200/JCO.2005.01.0934 on September 26 2005

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ghobrial, I. M. Articles by McGregor, C. G. Search for Related Content PubMed PubMed Citation Articles by Ghobrial, I. M. Articles by McGregor, C. G.

Prognostic Analysis for Survival in Adult Solid Organ Transplant Recipients With Post-Transplantation Lymphoproliferative Disorders

From the Division of Hematology, Department of Internal Medicine, Department of Biostatistics, Department of Pathology, Division of Infectious Diseases, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Division of Nephrology, Division of Transplantation Surgery, and Department of Surgery, Mayo Clinic, Rochester, MN

Address reprint requests to Thomas M. Habermann, MD, Division of Hematology, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, 200 First St, SW, Rochester, MN 55905; e-mail: habermann.thomas{at}mayo.edu

PURPOSE: The objective of this study was to determine prognostic factors for overall survival in patients with post-transplantation lymphoproliferative disorders (PTLDs).

PATIENTS AND METHODS: This study focused on the 107 adult solid organ transplantation patients who were diagnosed with PTLDs at Mayo Clinic (Rochester, MN) between December 1970 and May 2003.

RESULTS: The median age at the time of diagnosis was 48 years (range, 15 to 75 years). Extranodal disease including grafted organ involvement was present in 85 patients (80%). The graft organ was involved in 30 patients (28%). At the time of these analyses, 62 patients (58%) had died. The median survival for the entire cohort was 31.5 months (95% CI, 10.7 to 72.5 months). The median follow-up of living patients was 51.8 months (range, 5.6 to 202.6 months). In univariate analyses for overall survival from the time of PTLD diagnosis, the following poor prognostic factors were identified: poor performance status with Eastern Cooperative Oncology Group levels 3 and 4 (P < .0001), grafted organ involvement (P = .0005), the presence of one or more extranodal sites (P = .005), both nodal and extranodal disease (P = .002), high International Prognostic Index (P = .006), advanced stage (P = .001), and elevated lactate dehydrogenase (P = .03). A final multivariable model for survival was constructed using three factors: poor performance status (3 to 4), monomorphic disease, and graft organ involvement.

CONCLUSION: A prognostic model has been developed for PTLD patients using one center's 30 years of experience. We propose additional confirmation and validation of these prognostic factors in larger prospective studies.

Supported in part by Grant No. CA P50 CA97274, the Lymphoma Research Foundation, an ASCO Young Investigator Award, and an ASH Scholar award (I.G.). I.G. is a Lymphoma Research Scholar.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				B. Maecker, T. Jack, M. Zimmermann, H. Abdul-Khaliq, M. Burdelski, A. Fuchs, P. Hoyer, S. Koepf, U. Kraemer, G. F. Laube, et al. CNS or Bone Marrow Involvement As Risk Factors for Poor Survival in Post-Transplantation Lymphoproliferative Disorders in Children After Solid Organ Transplantation J. Clin. Oncol., November 1, 2007; 25(31): 4902 - 4908. [Abstract] [Full Text] [PDF]

				N. A. Bakker and G. W. van Imhoff Post-transplant lymphoproliferative disorders: from treatment to early detection and prevention? Haematologica, November 1, 2007; 92(11): 1447 - 1450. [Full Text] [PDF]

				J.-J. Lee, M. S. Lam, and A. Rosenberg Role of Chemotherapy and Rituximab for Treatment of Posttransplant Lymphoproliferative Disorder in Solid Organ Transplantation Ann. Pharmacother., October 1, 2007; 41(10): 1648 - 1659. [Abstract] [Full Text] [PDF]

				A. S. LaCasce Post-transplant lymphoproliferative disorders. Oncologist, June 1, 2006; 11(6): 674 - 680. [Abstract] [Full Text] [PDF]